- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Pemetrexed, Cisplatin, Bevacizumab
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Lake Success, New York • New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 961–984
of 1,758
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Unresectable Locally Advanced NSCLC
- Interventions
- Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta
- Drug
- Lead sponsor
- Mt. Sinai Medical Center, Miami
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Miami Beach, Florida
- Conditions
- Endometrial Cancer
- Interventions
- Gemcitabine, Cisplatin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 3
- States / cities
- Houston, Texas
- Conditions
- HPV-Associated Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage, HPV-Related Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Pathologic Stage
- Interventions
- NavDx HPV ctDNA Testing, Radiotherapy, Chemotherapy drug
- Device · Radiation · Drug
- Lead sponsor
- Jonathan Schoenfeld, MD, MPH
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Urothelial Cancer
- Interventions
- Iza-bren, Cisplatin, Gemcitabine, Carboplatin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 35
- States / cities
- Gilbert, Arizona • Fullerton, California • Palo Alto, California + 26 more
- Conditions
- Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
- Interventions
- Patritumab Deruxtecan, Platinum-based chemotherapy
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 586 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 23
- States / cities
- Anchorage, Alaska • Springdale, Arkansas • Duarte, California + 18 more
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Cisplatin, Docetaxel, Erlotinib, Erlotinib Hydrochloride, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Cancer
- Interventions
- cisplatin, gefitinib, gemcitabine hydrochloride
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Wilmington, Delaware
- Conditions
- Lung Cancer
- Interventions
- bexarotene, capecitabine, carboplatin, cisplatin, docetaxel, tretinoin
- Drug
- Lead sponsor
- Raghu Nandan, M.D., Inc
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Lakewood, California
- Conditions
- Anemia, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Neutropenia
- Interventions
- darbepoetin alfa, pegfilgrastim, cisplatin, docetaxel, BNP7787
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 64
- States / cities
- Mountain View, California • Lewes, Delaware • Newark, Delaware + 42 more
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- E7389 28 Day Cycle, E7389 21 Day Cycle
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 13
- States / cities
- Gilroy, California • Ocala, Florida • Baltimore, Maryland + 10 more
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Penpulimab, placebo
- Drug
- Lead sponsor
- Akeso
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 5
- States / cities
- Duarte, California • Atlanta, Georgia • Ann Arbor, Michigan + 1 more
- Conditions
- Pancreatic Cancer
- Interventions
- Irinotecan, Cisplatin, Olaparib (for levels 1 and 5), Olaparib (for dose level 2), Mitomycin-C
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • New York, New York
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Tomivosertib, Pembrolizumab, Pemetrexed
- Drug · Biological
- Lead sponsor
- Effector Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 131
- States / cities
- Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 105 more
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Abraxane, Cetuximab, Cisplatin, 5-FU, Radiation (Post induction)
- Drug · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Small-Cell Lung Cancer
- Interventions
- Durvalumab, AZD2811, Carboplatin, Cisplatin, Etoposide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Anaplastic Ependymoma, Brain Ependymoma, Cellular Ependymoma, Clear Cell Ependymoma, Ependymoma, Papillary Ependymoma
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Cisplatin, Clinical Observation, Cyclophosphamide, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Mesna, Vincristine
- Radiation · Drug · Other + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 479 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 181
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 135 more
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Leucovorin Calcium, Methotrexate, Thiotepa, Vincristine Sulfate
- Radiation · Procedure · Drug + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2024
- U.S. locations
- 87
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 72 more
- Conditions
- Ovarian Cancer, Malignant Female Reproductive System Neoplasm, Cancer, Ovarian Tumor, Ovarian Epithelial Cancer Recurrent
- Interventions
- DOXIL/CAELYX, ATI-0918
- Drug
- Lead sponsor
- Azaya Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Yakima, Washington
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- NKTR-214, Pembrolizumab, Cisplatin, Carboplatin, Nab paclitaxel, Paclitaxel, Pemetrexed, Atezolizumab
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 23
- States / cities
- Fayetteville, Arkansas • San Francisco, California • Aurora, Colorado + 19 more
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Durvalumab + Tremelimumab in combination with carboplatin and etoposide, Durvalumab in combination with carboplatin and etoposide
- Combination Product
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Bile Duct Cancer, Intrahepatic Cholangiocarcinoma
- Interventions
- Melphalan/HDS, Cisplatin and Gemcitabine
- Combination Product · Drug
- Lead sponsor
- Delcath Systems Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- Durham, North Carolina • Columbus, Ohio • Memphis, Tennessee
- Conditions
- Bladder Cancer, Muscle-invasive Bladder Cancer
- Interventions
- Methotrexate, Doxorubicin, vinblastine, cisplatin, Pegfilgrastim
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Burlington, Massachusetts • Pittsburgh, Pennsylvania
- Conditions
- Ovarian Cancer
- Interventions
- Chemotherapy + avelumab followed by avelumab + talazoparib, Chemotherapy followed by talazoparib maintenance, Chemotherapy + bevacizumab followed by bevacizumab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 26 more